Dr Priscilla Brastianos, page-123

@needle thanks for the detailed response! You really know your stuff!

The fact that paxalisisb is likely effective on 43 percent, only on that crosses the BBB and id in other trials speaks volumes to the clinician industries view on the probable outcomes of paxalisib as a first or second line treatment!!

This must be giving a good deal of hope to sufferers watching this, which is the point after all, and may be some kind of insurance for us we see how our luck goes in health!

I feel sorry for those that feel a need to attempt, and poorly, this drugs obvious continued success at a conservative and step by step ethical and utilising highly regarded entities to completed these studies!

Great to have such an inspirational person like DR Brastiano working on our drug.